Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 6991 to 7005 of 7679 results

  1. Lapatinib for breast cancer (first line use in advanced or metastatic hormone-sensitive breast cancer) [ID115]

    Discontinued [GID-TAG404]

    Technology appraisal guidance
    Discontinued

  2. Psoriasis - briakinumab (suspended) [ID65]

    Discontinued [GID-TAG412]

    Technology appraisal guidance
    Discontinued

  3. Avelumab for previously treated platinum-resistant ovarian cancer ID1497

    In development [GID-TA10404] Expected publication date: TBC

    Technology appraisal guidance
    In development

  4. Hepatitis B (adults) - entecavir and tenofovir disoproxil fumarate [ID111]

    Discontinued [GID-TAG414]

    Technology appraisal guidance
    Discontinued

  5. Nivolumab with ipilimumab for untreated recurrent or metastatic squamous cell cancer of the head and neck cancer [ID1429]

    Discontinued [GID-TA10512]

    Technology appraisal guidance
    Discontinued

  6. Veliparib in combination for treating BRCA-positive, HER2-negative breast advanced cancer [ID1404]

    Discontinued [GID-TA10327]

    Technology appraisal guidance
    Discontinued

  7. Nivolumab for small-cell lung cancer after platinum-based chemotherapy [ID1126]

    Discontinued [GID-TA10158]

    Technology appraisal guidance
    Discontinued

  8. Nintedanib for untreated malignant pleural mesothelioma [ID1424]

    Discontinued [GID-TA10359]

    Technology appraisal guidance
    Discontinued

  9. Pembrolizumab for previously treated metastatic triple negative breast cancer [ID1246]

    Discontinued [GID-TA10295]

    Technology appraisal guidance
    Discontinued

  10. Pexidartinib for treating symptomatic tenosynovial giant cell tumour [ID1682]

    Discontinued [GID-TA10609]

    Technology appraisal guidance
    Discontinued

  11. Rivaroxaban for the prevention of venous thromboembolism in people hospitalised for acute medical conditions [ID463]

    Discontinued [GID-TAG427]

    Technology appraisal guidance
    Discontinued

  12. Cetuximab for the treatment of advanced non-small-cell lung cancer [ID9]

    Discontinued [GID-TAG395]

    Technology appraisal guidance
    Discontinued

  13. Lapatinib in combination with paclitaxel for the first-line treatment of metastatic breast cancer which over-expresses ErbB2 (HER2) receptor [ID517]

    Discontinued [GID-TAG436]

    Technology appraisal guidance
    Discontinued

  14. Pembrolizumab with lenvatinib for untreated advanced melanoma [ID3948]

    In development [GID-TA10848] Expected publication date: TBC

    Technology appraisal guidance
    In development

  15. Lumacaftor with ivacaftor for treating cystic fibrosis in children aged 2 to 11 years old homozygous for the F508del mutation [ID1486]

    Discontinued [GID-TA10390]

    Technology appraisal guidance
    Discontinued